 VERSATILE-002 Trial for First Line Treatment of RecurrentMetastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA is Now Open and Recruiting Patients VERSATILE-002 Trial for First Line Treatment of RecurrentMetastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA is Now Open and Recruiting Patients 